StockData
Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc. (PHAT) stock

PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 4/30
$5.30−0.20 (-3.64%)

Close on Nov 18, 2026Market cap $430.84MP/E –Yield –

Phathom Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Phathom Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $274.88M, up 86.8% year over year. For fiscal 2025 it was $175.11M, up 216.9% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$175.11M+216.9%
FY2024Dec 31, 2024$55.25M+8001.5%
FY2023Dec 31, 2023$682.00K–
FY2022Dec 31, 2022$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$84.72M+71.1%
Q2 FY2026Jun 30, 2026$74.27M+88.0%
Q1 FY2026Mar 31, 2026$58.30M+104.4%
Q4 FY2025Dec 31, 2025$57.58M+94.1%
Q3 FY2025Sep 30, 2025$49.50M+202.7%
Q2 FY2025Jun 30, 2025$39.50M+439.4%
Q1 FY2025Mar 31, 2025$28.52M+1391.6%
Q4 FY2024Dec 31, 2024$29.66M+4249.6%
Q3 FY2024Sep 30, 2024$16.35M–
Q2 FY2024Jun 30, 2024$7.32M–
Q1 FY2024Mar 31, 2024$1.91M–
Q4 FY2023Dec 31, 2023$682.00K–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$0–
Q1 FY2023Mar 31, 2023$0–

More Phathom Pharmaceuticals figures

See a number that looks wrong?